A recent global study published in The Lancet projects that cases of liver cancer could nearly double by 2050, increasing from over 850,000 in 2022 to more than 1.5 million. Liver cancer ranks as the sixth most common cancer worldwide and is the third deadliest, with 5-year survival rates varying between 5% and 30%. The study highlights that approximately 60% of liver cancer cases are preventable through targeted public health interventions.
Key preventable risk factors identified include hepatitis B and C infections, excessive alcohol consumption, and liver diseases linked to obesity and metabolic disorders. Vaccination against hepatitis B is highly effective, providing protection for about 95% of recipients, while antiviral treatments for hepatitis C can cure nearly 98% of those infected. However, vaccine hesitancy and misinformation pose significant barriers to increasing vaccination rates, particularly in regions such as Africa, where coverage for the hepatitis B vaccine is only 17%.
Alcohol consumption is another major contributor to liver cancer, with around 400 million individuals affected by alcohol use disorder globally. Even moderate drinking can elevate cancer risk. Policy measures like alcohol taxes and educational initiatives could help mitigate this issue.
Additionally, metabolic dysfunction-associated steatotic liver disease (MASLD), which affects 40% of the global population, is primarily linked to obesity and type 2 diabetes. Promoting a balanced diet and regular physical activity may help reduce obesity rates, thereby lowering liver cancer risks.
Given the low survival rates and high treatment costs associated with advanced liver cancer, the study emphasizes the necessity of preventive strategies to avert a potential public health crisis by 2050.